RxDoctor Payments Data

Allie Black, PA

Physician Assistant · Odessa, TXNPI 1851660336

Payments from drug & device makers

$2,266in general payments, 2019–2025

Across 132 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$555
  • Novo Nordisk$353
  • AstraZeneca$306
  • Boehringer Ingelheim$294
  • Abbott$268
  • GSK$143
  • plus $347 from 9 others

What the payments were for

  • Food & beverage$2,266100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,266 in reported general payments places this provider in the 75th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$40,820
Medicare patients
136
Services billed
5,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$102,119
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$49,528
MounjaroTirzepatide42$47,337
FarxigaDapagliflozin Propanediol39$30,897
JardianceEmpagliflozin34$28,896
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$28,061
EliquisApixaban32$26,735
LinzessLinaclotide31$22,076
JanuviaSitagliptin Phosphate19$21,460
ProliaDenosumab12$20,476
XareltoRivaroxaban22$15,204
TradjentaLinagliptin12$12,916
Combivent RespimatIpratropium/Albuterol Sulfate12$7,399
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$4,656
Duloxetine Hcl144$3,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$353$102,11960 claims
AstraZenecaFarxiga, Breztri Aerosphere$306$58,95782 claims
GSKTrelegy Ellipta$143$49,52850 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$294$49,21258 claims
Lilly USA, LLCMounjaro$555$47,33742 claims
PfizerEliquis$117$26,73532 claims
MerckJanuvia$12$21,46019 claims
AmgenProlia$62$20,47612 claims
Johnson & JohnsonXarelto$18$15,20422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →